Literature DB >> 10199392

Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3.

K N Potter1, Y Li, R A Mageed, R Jefferis, J D Capra.   

Abstract

The mouse monoclonal antibody (mAb) D12 specifically binds in the variable region (idiotype) of human V(H)3 encoded antibodies. We used mutational analysis to determine the subregions of a V(H)3 encoded antibody which effect the interaction with mAb D12. Recombinant antibodies composed of mutant heavy chains were produced using the baculovirus expression system. The results of this topographical study indicate that the combined conformations of FRI, CDR2 and FR3 are critical for mAb D12 binding. MAb D12 binding was not effected either by the heavy chain CDR3 sequence nor by the light chain. We previously demonstrated that structures within the same three subregions are required for the B cell superantigen Staphylococcal protein A (SPA) binding to V(H)3 encoded antibodies. Thus, some anti-idiotypic antibodies can interact with antibodies in a similar fashion to superantigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10199392     DOI: 10.1016/s0161-5890(98)00103-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma.

Authors:  S Gharagozloo; R A Sharifian; R A Mageed; F Shokri
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 4.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.

Authors:  Andrew D Tustian; Christine Endicott; Benjamin Adams; John Mattila; Hanne Bak
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

6.  Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System.

Authors:  Narjes Shokrollahi; Mahdi Habibi-Anbouhi; Ali Jahanian-Najafabadi; Ehsan Alirahimi; Mahdi Behdani
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.